Astellas gives updates on Izervay security, part 1 geographic atrophy trial

PARK CITY, Utah — On this Healio Video Perspective from Medical Trials on the Summit, Carolyn Sasse of Astellas highlights the corporate’s ophthalmology pipeline.

Sasse gives updates about post-marketing security information for Izervay (avacincaptad pegol intravitreal resolution) and a part 1 trial that’s at the moment recruiting sufferers with geographic atrophy secondary to age-related macular degeneration.

“Over the previous decade, now we have established a number one early-stage ophthalmology pipeline that features cell and gene therapies to deal with illnesses corresponding to geographic atrophy and glaucoma, in addition to inherited retinal illnesses corresponding to Stargardt and retinitis pigmentosa,” she mentioned.

Printed by:

Sources/Disclosures

Collapse

Supply:

Healio Interviews

Disclosures:
Sasse studies being the event head of cell and gene remedy at Astellas.

Add subject to electronic mail alerts

Obtain an electronic mail when new articles are posted on

Please present your electronic mail deal with to obtain an electronic mail when new articles are posted on .

” data-action=subscribe>
Subscribe

We had been unable to course of your request. Please attempt once more later. In case you proceed to have this difficulty please contact [email protected].

Again to Healio